• Publications
  • Influence
GMCSF‐armed vaccinia virus induces an antitumor immune response
Oncolytic Western Reserve strain vaccinia virus selective for epidermal growth factor receptor pathway mutations and tumor‐associated hypermetabolism was armed with human granulocyte‐macrophageExpand
  • 29
  • 3
  • PDF
Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses.
Pancreatic ductal adenocarcinoma (PDA) is characterized by its highly immunosuppressive tumor microenvironment (TME) that limits T cell infiltration and induces T cell hypofunction.Expand
  • 70
  • 2
  • PDF
Oncolytic virotherapy for treatment of breast cancer, including triple-negative breast cancer
ABSTRACT Breast cancer is a heterogeneous disease, characterized by several distinct biological subtypes, among which triple-negative breast cancer (TNBC) is one associated with a poor prognosis.Expand
  • 16
  • 2
  • PDF
TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade
ABSTRACT Releasing the patient's immune system against their own malignancy by the use of checkpoint inhibitors is delivering promising results. However, only a subset of patients currently benefitExpand
  • 42
  • 2
Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy
Adoptive cell therapy holds much promise in the treatment of cancer but results in solid tumors have been modest. The notable exception is tumor-infiltrating lymphocyte (TIL) therapy of melanoma, butExpand
  • 35
  • 1
Adenoviral Delivery of Tumor Necrosis Factor-α and Interleukin-2 Enables Successful Adoptive Cell Therapy of Immunosuppressive Melanoma.
Adoptive T-cell transfer is a promising treatment approach for metastatic cancer, but efficacy in solid tumors has only been achieved with toxic pre- and postconditioning regimens. Thus, adoptiveExpand
  • 24
  • 1
  • PDF
Adenoviral production of interleukin‐2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy
Systemic high dose interleukin‐2 (IL‐2) postconditioning has long been utilized in boosting the efficacy of T cells in adoptive cell therapy (ACT) of solid tumors. The resulting severe off‐targetExpand
  • 9
  • 1
Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity
Background Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT). However, the immunosuppressiveExpand
  • 8
  • 1
31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016): part two
About this supplement These abstracts have been published as part of Journal for ImmunoTherapy of Cancer Volume 4 Suppl 1, 2016. The full contents of the supplement are available online atExpand
  • 9
  • 1
Abscopal Effect in Non-injected Tumors Achieved with Cytokine-Armed Oncolytic Adenovirus
Cancer treatment with local administration of armed oncolytic viruses could potentially induce systemic antitumor effects, or the abscopal effect, as they self-amplify in tumors, induce dangerExpand
  • 20